These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study. Kang MJ; Choi JY; Sim WY; Lew BL J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771 [No Abstract] [Full Text] [Related]
3. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? Arias-Santiago S; Camacho-Martínez FM Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study). Yamanishi T; Asakura H; Seki N; Tokunaga S Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M; J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187 [TBL] [Abstract][Full Text] [Related]
6. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN; BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004 [TBL] [Abstract][Full Text] [Related]
7. Contemporary issues with pharmacotherapy for lower urinary tract symptoms. Osman N; Chapple CR Int J Clin Pract; 2014 May; 68(5):541-2. PubMed ID: 24750526 [TBL] [Abstract][Full Text] [Related]
8. Dutasteride in Androgenetic Alopecia: An Update. Arif T; Dorjay K; Adil M; Sami M Curr Clin Pharmacol; 2017; 12(1):31-35. PubMed ID: 28294070 [TBL] [Abstract][Full Text] [Related]
9. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Fertig RM; Gamret AC; Darwin E; Gaudi S Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447628 [TBL] [Abstract][Full Text] [Related]
10. [Combination drug therapy in patients with BPH]. Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142 [TBL] [Abstract][Full Text] [Related]
11. sQuiz your knowledge: Polycyclic annular plaques on the trunk following dutasteride treatment. Ruiz-Villaverde R; Ayen-Rodriguez A; Llamas-Molina JM Eur J Dermatol; 2020 Aug; 30(4):452-453. PubMed ID: 32969816 [No Abstract] [Full Text] [Related]
12. Angioedema-like contact dermatitis caused by mesotherapy with dutasteride. Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Alonso-Carpio M; Talamantes CS; Zaragoza-Ninet MG; Zaragoza-Ninet V Contact Dermatitis; 2020 Sep; 83(3):246-247. PubMed ID: 32356373 [No Abstract] [Full Text] [Related]
13. Androgenetic alopecia; drug safety and therapeutic strategies. Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345 [TBL] [Abstract][Full Text] [Related]
14. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Traish A; Haider KS; Doros G; Haider A Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494 [TBL] [Abstract][Full Text] [Related]
15. The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health. Said MA; Mehta A Curr Urol Rep; 2018 Jun; 19(8):65. PubMed ID: 29909472 [TBL] [Abstract][Full Text] [Related]
16. [Hepatotoxicity by tamsulosin / dutasteride: report of a probable case]. Yance S; Montes P Rev Gastroenterol Peru; 2023; 43(3):269-272. PubMed ID: 37890853 [TBL] [Abstract][Full Text] [Related]
17. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453 [TBL] [Abstract][Full Text] [Related]
18. Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer. Figg WD; Thompson IM JAMA Oncol; 2015 Jun; 1(3):321-2. PubMed ID: 26181178 [No Abstract] [Full Text] [Related]
19. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. Chung HC; Lee S; Lee WS J Dermatol; 2017 Dec; 44(12):1408-1409. PubMed ID: 27988928 [No Abstract] [Full Text] [Related]
20. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. Chou CH; Lin CL; Lin MC; Sung FC; Kao CH J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]